Skip to main content
Terug
Watch Compare

Jaguar Health, Inc.

Datakwaliteit: 100%
JAGX
Nasdaq Manufacturing Chemicals
€ 0,38
▼ € 0,02 (-5,01%)
Marktkapitalisatie: 4,71 M
Prijs
€ 0,38
Marktkapitalisatie
4,71 M
Dagbereik
€ 0,37 — € 0,40
52-Weeksbereik
€ 0,31 — € 15,48
Volume
655.042
Openen € 0,40
50D / 200D Gem.
€ 0,58
34,42% below
50D / 200D Gem.
€ 1,52
75,06% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -23,70 M
Capital efficient — spends only 0,14% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-1,52%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-953,38%
Onder sectorgemiddelde (-53,41%)
ROIC-223,87%
Net Margin-465,42%
Op. Margin-398,82%

Veiligheid

Debt / Equity
N/A
Current Ratio0,81
Interest Coverage-685,19

Waardering

PE (TTM)
-0,09
Boven sectorgemiddelde (-1,48)
P/B Ratio1,08
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,1 -1,5
P/B 1,1 1,6
ROE % -953,4 -53,4
Net Margin % -465,4 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -1,52% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 11,51 M Net Income (TTM) -53,58 M
ROE -953,38% ROA -109,63%
Gross Margin N/A Operating Margin -398,82%
Net Margin -465,42% Free Cash Flow (TTM) -23,70 M
ROIC -223,87% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,81
Interest Coverage -685,19 Asset Turnover 0,24
Working Capital -6,72 M Tangible Book Value -12,93 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,09 Forward P/E N/A
P/B Ratio 1,08 P/S Ratio 0,41
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -503,56%
Market Cap 4,71 M Enterprise Value 1,18 M
Per Share
EPS (Diluted TTM) -22,97 Revenue / Share 0,93
FCF / Share -1,91 OCF / Share -1,91
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,14% FCF Conversion 44,24%
SBC-Adj. FCF -24,72 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 11,51 M 11,69 M — 11,96 M —
Net Income -53,58 M -38,49 M -41,30 M -48,40 M -52,60 M
EPS (Diluted) -22,97 -130,69 -1,79 -36,18 -1,18
Gross Profit — — — — —
Operating Income -45,91 M -30,83 M -34,29 M -34,42 M -40,71 M
EBITDA — — — — —
R&D Expenses 24,97 M 16,54 M 18,60 M 17,65 M 15,08 M
SG&A Expenses — — — — —
D&A 1,91 M 1,90 M 2,01 M 1,98 M 1,72 M
Interest Expense 67.000,0 231.000,0 6,38 M 12,72 M 8,42 M
Income Tax 0,0 0,0 — 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 38,32 M 53,43 M 50,76 M 47,45 M 53,27 M
Total Liabilities 57,01 M 44,45 M 45,87 M 48,81 M 41,41 M
Shareholders' Equity -18,69 M 6,49 M 4,90 M -1,36 M 11,85 M
Total Debt — — — — —
Cash & Equivalents 968.000,0 8,00 M 6,47 M 5,47 M —
Current Assets 20,35 M 32,20 M 27,96 M 22,32 M 28,43 M
Current Liabilities 40,65 M 19,70 M 13,99 M 30,34 M 15,47 M